Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Gamechanger-Deal am Horizont: Entscheidende Nachrichten in 2025 erwartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12ETN | ISIN: CA98420N1050 | Ticker-Symbol: XP0
Tradegate
23.04.25
17:33 Uhr
33,200 Euro
0,000
0,00 %
1-Jahres-Chart
XENON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
XENON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
32,60033,00011:34
32,60033,00010:55

Aktuelle News zur XENON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.04.Xenon Pharmaceuticals Inc.: Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 20251
17.03.Xenon Pharmaceuticals Inc. - 8-K, Current Report4
12.03.Xenon Pharmaceuticals Inc.: Xenon to Present at Stifel 2025 Virtual CNS Forum1
05.03.Xenon Pharmaceuticals Inc. - 8-K, Current Report1
XENON PHARMACEUTICALS Aktie jetzt für 0€ handeln
27.02.Xenon Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans-
27.02.Xenon Pharmaceuticals Inc.: Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update178- Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch - First of three planned Phase 3 azetukalner MDD studies...
► Artikel lesen
27.02.Xenon Pharmaceuticals Inc. - 10-K, Annual Report-
20.02.Xenon Pharmaceuticals Inc.: Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 20251
17.01.Xenon Pharmaceuticals Inc. - 8-K, Current Report5
13.01.Xenon Pharmaceuticals Inc.: Xenon Outlines Key Corporate Milestone Opportunities for 2025138- Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner - First of three planned Phase 3 MDD...
► Artikel lesen
06.12.24Xenon Pharmaceuticals Inc.: Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024216- OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner...
► Artikel lesen
25.11.24Xenon Pharmaceuticals Inc.: Xenon to Showcase New Long-Term Azetukalner Data at AES 20241
12.11.24Xenon Pharma GAAP EPS of -$0.81 in-line2
12.11.24Xenon Pharmaceuticals Inc.: Xenon Reports Q3 2024 Financial Results and Business Update252- Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 - Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES - Phase...
► Artikel lesen
12.11.24Xenon Pharmaceuticals Inc. - 10-Q, Quarterly Report-
11.11.24Xenon Pharma Q3 2024 Earnings Preview1
11.11.24Earnings Preview: Xenon Pharmaceuticals1
05.11.24Xenon Pharmaceuticals Inc.: Xenon to Report Q3 2024 Financial Results on November 12, 20242
08.08.24Xenon Pharmaceuticals Inc.: Xenon Reports Q2 2024 Financial Results and Business Update146- Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025- MDD program on track with Phase 3 study expected to initiate in H2 2024- Multiple Kv7 and Nav1.7 candidates...
► Artikel lesen
28.05.24Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting147VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1